Drug Trial Radar · NCT06695130
Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
980
Actual
Start
Nov 18, 2024
Primary completion
Apr 3, 2026
Study completion Apr 3, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study VBT00002 is planned to be a Phase 1/2, randomized, modified double-blind, active-controlled, multi-center study to be conducted in approximately 980 adults aged 50 years and older in the United States. The purpose of the study is to assess the safety and immunogenicity of recombinant influenza vaccine (RIV) + adjuvanted recombinant COVID-19 vaccine (rC19) vaccine comprised of RIV combined with different recombinant Spike (rS) antigen levels of rC19 compared to RIV alone, rC19 (dose 1) alone, and RIV and rC19 (dose 1) (coadministered in opposite arms). Placebo will be coadministered in the RIV alone, rC19 (dose 1) alone, and RIV + rC19 study groups to control for the number of injections and to maintain observer blinding. Thus, each participant will receive two injections at enrollment, one in each deltoid muscle. Study details include: * The study duration will be approximately 12 months * Study intervention will be administered via a single intramuscular (IM) injection into the right and left deltoid muscles on Day(D) 01 * Dose escalation with sequential enrollment (sentinel cohort followed by main cohort for a given dose) * The visit frequency for participants will be D01 and D30, and D09-D366 (telephone call) Number of Participants: Approximately 980 participants are expected to be randomized.
Conditions
- COVID-19 Immunization
- Influenza Immunization
Interventions
RIV (recombinant influenza vaccine)Biological
Influenza, inactivated, split virus or surface antigen
rC19 (dose 1)Biological
Protein subunit
RIV + rC19 (dose 1)Biological
RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
RIV + rC19 (dose 2)Biological
RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
RIV + rC19 (dose 3)Biological
RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
RIV + rC19 (dose 4)Biological
RIV component: Influenza, inactivated, split virus or surface antigen NVXC19 component: Protein subunit
Placebo (0.9% NaCl)Other
Normal saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with immediate adverse events (AEs)Time frame: Immediate adverse events are any unsolicited systemic adverse events reported in the 30 minutes after vaccination
- Number of participants with solicited injection site reactionsTime frame: Up to 7 each days after vaccination
- Number of participants with solicited systemic reactionsTime frame: Up to 7 days after each vaccination
- Number of participants with unsolicited AEsTime frame: Up to 28 days after each vaccination
- Number of participants with adverse events of special interest (AESIs)Time frame: Up to 180 days after each vaccination
- Number of participants with medical attended adverse events (MAAEs)Time frame: Up to 180 days after each vaccination
- Number of participants with MAAEs relating to predefined PIMDsTime frame: From Day 182 through 12 months following the last study vaccination
- Number of participants with serious adverse events (SAEs)Time frame: Up to 180 days after each vaccination
- Number of participants with related SAEsTime frame: From Day 182 through 12 months following the last study intervention
- Number of participants with MAAEs relating to predefined PIMDs that meet the criteria for SAEsTime frame: From Day 182 through 12 months following the last study vaccination
- Geometric mean (GM) of HAI titers in all participantsTime frame: At Day 01 and Day 30
- Geometric mean ratio (GMR) of HAI titers in all participantsTime frame: At Day 01 and Day 30
- GM of SARS-CoV-2 neutralizing titers in all participantsTime frame: At Day 01 and Day 30
- GMR of SARS-CoV-2 neutralizing titers ratio D30/D01 in all participantsTime frame: At Day 01 and Day 30
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
Central Phoenix Medical Clinic- Site Number : 8400009
Phoenix, Arizona
Synexus Clinical Research US, Inc. - Cerritos- Site Number : 8400002
Cerritos, California
Synexus Clinical Research US - Vista- Site Number : 8400010
Vista, California
Optimal Research - Florida- Site Number : 8400006
Melbourne, Florida
Synexus Clinical Research US - Orlando- Site Number : 8400007
Orlando, Florida
Optimal Research - Illinois- Site Number : 8400008
Peoria, Illinois
Synexus Clinical Research US - Evansville- Site Number : 8400004
Evansville, Indiana
Walgreens Clinical Trials-Malden- Site Number : 8400012
Malden, Massachusetts
Synexus Clinical Research US - Minneapolis- Site Number : 8400011
Richfield, Minnesota
Synexus-Las Vegas- Site Number : 8400005
Las Vegas, Nevada
Synexus Clinical Research US - Cincinnati- Site Number : 8400003
Cincinnati, Ohio
Synexus Clinical Research US - Anderson- Site Number : 8400001
Anderson, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.